# La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is an other based in Waltham, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Waltham, United States
- **Region:** North America
- **Address:** Waltham, MA, United States
- **Assets under management:** Undisclosed
- **Website:** www.lajollapharmaceutical.com

## Regulatory record

- **Reports private funds:** No

## About

La Jolla Pharmaceutical Company, now branded as Innoviva Specialty Therapeutics, is a biotechnology firm that develops and commercializes therapies for critical care and infectious diseases. Its marketed products include GIAPREZA (angiotensin II) for vasodilatory shock, XACDURO (sulbactam; durlobactam) for Acinetobacter infections, XERAVA (eravacycline) for complicated intra-abdominal infections, and ZEVTERA (ceftobiprole medocaril sodium) for bacterial infections. The company also has NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in its pipeline. The company's strategy focuses on areas of high unmet medical need within hospitals, targeting both new standards of care and established treatments. Its geographic footprint includes the United States and global markets via partners. No AUM, deployment numbers, or team size have been disclosed. The firm's website provides product and pipeline details but does not offer financial or ownership information. No recent operational events from the last 24 months were found in available sources. The company's structural identity is as a diversified biotech firm distinct from family offices or asset managers.

## Sectors

- Biotech
- Pharmaceuticals
- Healthcare

## Questions

### What is the primary therapeutic focus of La Jolla Pharmaceutical Company?

La Jolla Pharmaceutical Company focuses on critical care and infectious diseases, with marketed products for vasodilatory shock, Acinetobacter infections, complicated intra-abdominal infections, and bacterial infections (per firm website).

### What products does La Jolla Pharmaceutical Company market?

The company markets GIAPREZA (angiotensin II), NUZOLVENCE (zoliflodacin), XACDURO (sulbactam for injection; durlobactam for injection), XERAVA (eravacycline), and ZEVTERA (ceftobiprole medocaril sodium for injection) (per firm website).

### Does La Jolla Pharmaceutical Company have a pipeline product?

NUZOLVENCE (zoliflodacin) is listed as a marketed product, though it is in development for uncomplicated gonorrhea. No other pipeline details were available from the firm's website.

### Where is La Jolla Pharmaceutical Company headquartered?

The company is headquartered in Waltham, Massachusetts, United States (per firm website).

### Who owns La Jolla Pharmaceutical Company?

Ownership is not disclosed on the firm's website. No public information about the founding family or principals was available in the provided sources.

## Related profiles

- [Laidlaw](https://altss.com/profile/laidlaw)
- [MHC Software LLC](https://altss.com/profile/mhc-software-llc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/la-jolla-pharmaceutical-company

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology